Cargando…

Serum amyloid A in cats with renal azotemia

BACKGROUND AND AIM: The concentration of the feline acute-phase protein serum amyloid A (SAA) increases in cats with acute inflammatory diseases. However, it is unclear whether SAA concentration increases in cats with azotemic kidney disease or whether it can aid in differentiating acute kidney inju...

Descripción completa

Detalles Bibliográficos
Autores principales: Degenhardt, Laura, Dorsch, Roswitha, Hartmann, Katrin, Dörfelt, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Veterinary World 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521177/
https://www.ncbi.nlm.nih.gov/pubmed/37766698
http://dx.doi.org/10.14202/vetworld.2023.1673-1681
_version_ 1785110077190963200
author Degenhardt, Laura
Dorsch, Roswitha
Hartmann, Katrin
Dörfelt, René
author_facet Degenhardt, Laura
Dorsch, Roswitha
Hartmann, Katrin
Dörfelt, René
author_sort Degenhardt, Laura
collection PubMed
description BACKGROUND AND AIM: The concentration of the feline acute-phase protein serum amyloid A (SAA) increases in cats with acute inflammatory diseases. However, it is unclear whether SAA concentration increases in cats with azotemic kidney disease or whether it can aid in differentiating acute kidney injury (AKI) from chronic kidney disease (CKD). Similarly, whether SAA concentration can be used as a prognostic marker is also unclear. Therefore, this study aimed to evaluate the SAA concentrations in cats with azotemic kidney disease and determine whether SAA concentrations can be used to differentiate between AKI, CKD, and “acute on CKD” (AoC). In addition, we evaluated whether SAA concentration could serve as a prognostic parameter. Moreover, we determined the correlations between SAA concentration and temperature; creatinine, urea, and albumin concentrations; leukocyte count; and urine protein/creatinine (UP/C). MATERIALS AND METHODS: Forty-eight client-owned azotemic cats (creatinine >250 μmol/L) were included in this prospective study. Cats with pre- and post-renal azotemia were excluded from the study. The causes of azotemia were differentiated into AKI, CKD, and AoC. The SAA concentrations were analyzed through turbidimetric immunoassay at the time of admission. Data were analyzed using the Mann–Whitney U, Kruskal–Wallis, Chi-Square, Fisher’s exact, and Spearman correlation tests. p ≤ 0.05 was considered statistically significant. RESULTS: Serum amyloid A concentration increased in 5/12 cats with AKI, 7/22 cats with CKD, and 9/14 cats with AoC (p = 0.234). The median SAA concentration in cats with AKI, CKD, and AoC whose SAA concentration was ≥5 mg/L was 174 mg/L (10–281 mg/L), 125 mg/L (6–269 mg/L), and 143 mg/L (7–316 mg/L), respectively (p = 0.697), with no significant differences observed between the groups. The median SAA concentration did not differ significantly between survivors (125 mg/L, 10–316 mg/L) and non-survivors (149 mg/L, 6–281 mg/L; p = 0.915) with SAA concentration ≥5 mg/L. CONCLUSION: Serum amyloid A concentration increased in 44% of the cats with azotemia. However, it cannot be used to differentiate AKI from CKD or as a prognostic marker. Serum amyloid A concentration was correlated with neutrophil count, albumin concentration, and UP/C, and the presence of comorbidities may influence SAA concentration.
format Online
Article
Text
id pubmed-10521177
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Veterinary World
record_format MEDLINE/PubMed
spelling pubmed-105211772023-09-27 Serum amyloid A in cats with renal azotemia Degenhardt, Laura Dorsch, Roswitha Hartmann, Katrin Dörfelt, René Vet World Research Article BACKGROUND AND AIM: The concentration of the feline acute-phase protein serum amyloid A (SAA) increases in cats with acute inflammatory diseases. However, it is unclear whether SAA concentration increases in cats with azotemic kidney disease or whether it can aid in differentiating acute kidney injury (AKI) from chronic kidney disease (CKD). Similarly, whether SAA concentration can be used as a prognostic marker is also unclear. Therefore, this study aimed to evaluate the SAA concentrations in cats with azotemic kidney disease and determine whether SAA concentrations can be used to differentiate between AKI, CKD, and “acute on CKD” (AoC). In addition, we evaluated whether SAA concentration could serve as a prognostic parameter. Moreover, we determined the correlations between SAA concentration and temperature; creatinine, urea, and albumin concentrations; leukocyte count; and urine protein/creatinine (UP/C). MATERIALS AND METHODS: Forty-eight client-owned azotemic cats (creatinine >250 μmol/L) were included in this prospective study. Cats with pre- and post-renal azotemia were excluded from the study. The causes of azotemia were differentiated into AKI, CKD, and AoC. The SAA concentrations were analyzed through turbidimetric immunoassay at the time of admission. Data were analyzed using the Mann–Whitney U, Kruskal–Wallis, Chi-Square, Fisher’s exact, and Spearman correlation tests. p ≤ 0.05 was considered statistically significant. RESULTS: Serum amyloid A concentration increased in 5/12 cats with AKI, 7/22 cats with CKD, and 9/14 cats with AoC (p = 0.234). The median SAA concentration in cats with AKI, CKD, and AoC whose SAA concentration was ≥5 mg/L was 174 mg/L (10–281 mg/L), 125 mg/L (6–269 mg/L), and 143 mg/L (7–316 mg/L), respectively (p = 0.697), with no significant differences observed between the groups. The median SAA concentration did not differ significantly between survivors (125 mg/L, 10–316 mg/L) and non-survivors (149 mg/L, 6–281 mg/L; p = 0.915) with SAA concentration ≥5 mg/L. CONCLUSION: Serum amyloid A concentration increased in 44% of the cats with azotemia. However, it cannot be used to differentiate AKI from CKD or as a prognostic marker. Serum amyloid A concentration was correlated with neutrophil count, albumin concentration, and UP/C, and the presence of comorbidities may influence SAA concentration. Veterinary World 2023-08 2023-08-19 /pmc/articles/PMC10521177/ /pubmed/37766698 http://dx.doi.org/10.14202/vetworld.2023.1673-1681 Text en Copyright: © Degenhardt, et al. https://creativecommons.org/licenses/by/4.0/Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Degenhardt, Laura
Dorsch, Roswitha
Hartmann, Katrin
Dörfelt, René
Serum amyloid A in cats with renal azotemia
title Serum amyloid A in cats with renal azotemia
title_full Serum amyloid A in cats with renal azotemia
title_fullStr Serum amyloid A in cats with renal azotemia
title_full_unstemmed Serum amyloid A in cats with renal azotemia
title_short Serum amyloid A in cats with renal azotemia
title_sort serum amyloid a in cats with renal azotemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521177/
https://www.ncbi.nlm.nih.gov/pubmed/37766698
http://dx.doi.org/10.14202/vetworld.2023.1673-1681
work_keys_str_mv AT degenhardtlaura serumamyloidaincatswithrenalazotemia
AT dorschroswitha serumamyloidaincatswithrenalazotemia
AT hartmannkatrin serumamyloidaincatswithrenalazotemia
AT dorfeltrene serumamyloidaincatswithrenalazotemia